Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender

Pharmacogenetics

Volumn 6, Issue 1, 1996, Pages 93-101

  Ratain, Mark J ^a   Mick, Rosemarie ^a   Janisch, Linda ^a   Berezin, Frances ^a   Schilsky, Richard L ^a   Vogelzang, Nicholas J ^a   Kut, Michael ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

acetylation; antineoplastic; isoquinolines; phenotype

Indexed keywords

AMONAFIDE;

ACETYLATION; ACETYLATOR PHENOTYPE; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; FEMALE; GENDER; HUMAN; INDIVIDUALIZATION; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MODEL; MUCOSA INFLAMMATION; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; THORAX PAIN; VOMITING;

ACETYLATION; ADULT; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDES; ISOQUINOLINES; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NAPHTHALIMIDES; PHENOTYPE; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 0029919926     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199602000-00008     Document Type: Article

References (27)

1. Andersson BS, Beran M, Bakic M, Silberman LE, Newman RA, Zwelling LA. In vitro toxicity and DNA cleaving capacity of benziosoquinolinedione (nafidimide, NSC 308847) in human leukemia. Cancer Res 1987: 47, 1040-1044.
2. Berthou F, Flinois JP, Ratanasavanh D, Beaune P, Riche C, Guillouzo A. Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 1991: 19, 561-567.
3. Costanza ME, Berry D, Henderson IC, Ratain MJ, Wu K, Shapiro C, Duggan D, Kalra J, Berkowitz I, Lyss AP. Amonafide: an active agent in the treatment of previously untreated advanced breast cancer: a Cancer and Leukemia Group B study (CALGB 8642). Clin Cancer Res: in press.
4. Craig J, Crawford E, Phase II trial of amonafide in advanced prostate cancer. Proc Am Soc Clin Oncol 1989: 8, 147.
5. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase: Biochemical basis of familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988: 81, 47-51.
6. Felder TB, McLean MA, Vestal ML, Lu K, Farquhar D, Legha SS, Shah R, Newman RA. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC 308847) in humans. Drug Metab Dispos 1987: 15, 773-778.
7. Fuhr U, Anders E-M, Mahr G, Sorgel F, Staib AH. Inhibitory potency of quinolone anti-bacterial agents against cytochrome P4501A2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992: 36, 942-948.
8. Gupta E, Lestingi TM, Mick R, Ramirez J, Yokes EE, Ratain MJ. Metabolic fate of irinotecan (CPT-11) in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994: 54, 3723-3725.
9. Hsiang TH, Jiang JB, Liu LF. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs. Mol Pharmacol 1989: 36, 371-376.
10. Kornek G, Raderer M, Depisch D, Haider K, Fazeny B, Dittrich C, Scheithauer W. Amonafide as first-line chemotherapy for metastatic breast cancer. Eur J Cancer 1994: 30A, 398-400.
11. Legha SS, Ring S, Raber M, Felder TB, Newman RA, Krakoff IH. Phase I clinical investigation of benzisoquinolinedione. Cancer Treat Rep 1987: 71, 1165-1169.
12. Leiby JM, Malpeis L, Staubus AE, Kraut EH, Grever MR. Amonafide (NSC 308847): a clinical phase I study of two schedules of administration. Proc Am Assoc Cancer Res 1988: 29, 278.
13. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989: 7, 1816-1823.
14. Mick R, Ratain MJ. Statistical approaches to pharmacodynamic modeling: motivations, methods and misperceptions. Cancer Chemother Pharmacol 1993: 33, 1-9.
15. Milano G, Etienne MC, Cassuto-Vigvier E, Thyss A, Santini J, Frenay M, Renee N, Schneider M, Demard F. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992: 10, 1171-1175.
16. O'Brien S, Benvenuto JA, Estey E, Beran M, Felder TB, Keating M. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. Cancer Res 1991: 51, 935-938.
17. Ratain MJ, Staubus AE, Schilsky RL, Malpeis L. Limited sampling models for amonafide (NSC 308847) pharmacokinetics. Cancer Res 1988: 48, 4127-4130.
18. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther 1991a: 50, 573-579.
19. Ratain MJ, Mick R, Schilsky RL, Vogelzang NJ, Berezin F, Pharmacologically-based dosing of etoposide: A means of safely increasing dose-intensity. J Clin Oncol 1991b: 9, 1480-1486.
20. Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 1993: 53, 2304-2308.
21. Ratain MJ, Rosner G, Allen SL, Costanza ME, Van Echo DA, Henderson IC, Schilsky RL. Population pharmacodynamic study of amonafide: A Cancer and Leukemia Group B study. J Clin Oncol 1995: 13, 741-747.
22. Relling MV, Lin J-S, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferace, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992: 52, 643-658.
23. Saez R, Craig JB, Kuhn JG, Weiss GR, Koeller J, Phillips J, Havlin K, Harman G, Hardy J, Melink TJ, Sarosy GA, Von Hoff DD. Phase I clinical investigation of amonafide. J Clin Oncol 1989: 7, 1351-1358.
24. Scheithauer W, Dittrich C, Kornek G, Haider K, Linkesch W, Gisslinger H, Depisch D. Phase II study of amonafide in advanced breast cancer. Breast Cancer Res Treat 1991: 20, 63-67.
25. Sheiner LB, Beal S. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981: 4, 503-512.
26. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985: 37, 25-79.
27. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980: 32, 651-662.